132 related articles for article (PubMed ID: 27624965)
1. Mechanism of Poliovirus Resistance to Host Phosphatidylinositol-4 Kinase III β Inhibitor.
Arita M
ACS Infect Dis; 2016 Feb; 2(2):140-8. PubMed ID: 27624965
[TBL] [Abstract][Full Text] [Related]
2. Modulation of proteolytic polyprotein processing by coxsackievirus mutants resistant to inhibitors targeting phosphatidylinositol-4-kinase IIIβ or oxysterol binding protein.
Lyoo H; Dorobantu CM; van der Schaar HM; van Kuppeveld FJM
Antiviral Res; 2017 Nov; 147():86-90. PubMed ID: 29024767
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure.
Arita M
Microbiol Immunol; 2014 Apr; 58(4):239-56. PubMed ID: 24527995
[TBL] [Abstract][Full Text] [Related]
4. Poliovirus Evolution toward Independence from the Phosphatidylinositol-4 Kinase III β/Oxysterol-Binding Protein Family I Pathway.
Arita M; Bigay J
ACS Infect Dis; 2019 Jun; 5(6):962-973. PubMed ID: 30919621
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.
Arita M; Kojima H; Nagano T; Okabe T; Wakita T; Shimizu H
J Virol; 2011 Mar; 85(5):2364-72. PubMed ID: 21177810
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 4-kinase III beta is the target of oxoglaucine and pachypodol (Ro 09-0179) for their anti-poliovirus activities, and is located at upstream of the target step of brefeldin A.
Arita M; Philipov S; Galabov AS
Microbiol Immunol; 2015 Jun; 59(6):338-47. PubMed ID: 25891300
[TBL] [Abstract][Full Text] [Related]
7. A complex comprising phosphatidylinositol 4-kinase IIIβ, ACBD3, and Aichi virus proteins enhances phosphatidylinositol 4-phosphate synthesis and is critical for formation of the viral replication complex.
Ishikawa-Sasaki K; Sasaki J; Taniguchi K
J Virol; 2014 Jun; 88(12):6586-98. PubMed ID: 24672044
[TBL] [Abstract][Full Text] [Related]
8. High-Order Epistasis and Functional Coupling of Infection Steps Drive Virus Evolution toward Independence from a Host Pathway.
Arita M
Microbiol Spectr; 2021 Oct; 9(2):e0080021. PubMed ID: 34468191
[TBL] [Abstract][Full Text] [Related]
9. Model of OSBP-Mediated Cholesterol Supply to Aichi Virus RNA Replication Sites Involving Protein-Protein Interactions among Viral Proteins, ACBD3, OSBP, VAP-A/B, and SAC1.
Ishikawa-Sasaki K; Nagashima S; Taniguchi K; Sasaki J
J Virol; 2018 Apr; 92(8):. PubMed ID: 29367253
[TBL] [Abstract][Full Text] [Related]
10. Mutations in Encephalomyocarditis Virus 3A Protein Uncouple the Dependency of Genome Replication on Host Factors Phosphatidylinositol 4-Kinase IIIα and Oxysterol-Binding Protein.
Dorobantu CM; Albulescu L; Lyoo H; van Kampen M; De Francesco R; Lohmann V; Harak C; van der Schaar HM; Strating JR; Gorbalenya AE; van Kuppeveld FJ
mSphere; 2016; 1(3):. PubMed ID: 27303747
[TBL] [Abstract][Full Text] [Related]
11. Oxysterol-binding protein family I is the target of minor enviroxime-like compounds.
Arita M; Kojima H; Nagano T; Okabe T; Wakita T; Shimizu H
J Virol; 2013 Apr; 87(8):4252-60. PubMed ID: 23365445
[TBL] [Abstract][Full Text] [Related]
12. [Exploration for anti-enterovirus compounds and analysis on the mechanism of its inhibitory effect on virus infection].
Arita M
Uirusu; 2013; 63(1):93-102. PubMed ID: 24769585
[TBL] [Abstract][Full Text] [Related]
13. ACBD3 Is an Essential Pan-enterovirus Host Factor That Mediates the Interaction between Viral 3A Protein and Cellular Protein PI4KB.
Lyoo H; van der Schaar HM; Dorobantu CM; Rabouw HH; Strating JRPM; van Kuppeveld FJM
mBio; 2019 Feb; 10(1):. PubMed ID: 30755512
[TBL] [Abstract][Full Text] [Related]
14. New small-molecule inhibitors effectively blocking picornavirus replication.
Ford Siltz LA; Viktorova EG; Zhang B; Kouiavskaia D; Dragunsky E; Chumakov K; Isaacs L; Belov GA
J Virol; 2014 Oct; 88(19):11091-107. PubMed ID: 25008939
[TBL] [Abstract][Full Text] [Related]
15. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307.
Albulescu L; Bigay J; Biswas B; Weber-Boyvat M; Dorobantu CM; Delang L; van der Schaar HM; Jung YS; Neyts J; Olkkonen VM; van Kuppeveld FJM; Strating JRPM
Antiviral Res; 2017 Apr; 140():37-44. PubMed ID: 28088354
[TBL] [Abstract][Full Text] [Related]
16. Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection.
Arita M; Wakita T; Shimizu H
J Virol; 2012 May; 86(10):5541-53. PubMed ID: 22379090
[TBL] [Abstract][Full Text] [Related]
17. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection.
Arita M; Takebe Y; Wakita T; Shimizu H
J Gen Virol; 2010 Nov; 91(Pt 11):2734-44. PubMed ID: 20660150
[TBL] [Abstract][Full Text] [Related]
18. Essential domains of phosphatidylinositol-4 kinase III β required for enterovirus replication.
Arita M
Microbiol Immunol; 2019 Jul; 63(7):285-288. PubMed ID: 31166044
[TBL] [Abstract][Full Text] [Related]
19. Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication.
van der Schaar HM; van der Linden L; Lanke KH; Strating JR; Pürstinger G; de Vries E; de Haan CA; Neyts J; van Kuppeveld FJ
Cell Res; 2012 Nov; 22(11):1576-92. PubMed ID: 22945356
[TBL] [Abstract][Full Text] [Related]
20. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein.
Crotty S; Saleh MC; Gitlin L; Beske O; Andino R
J Virol; 2004 Apr; 78(7):3378-86. PubMed ID: 15016860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
